# Retatrutide + cagrilintide blend

Source: https://aminodesk.com/library/retatrutide-cagrilintide
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

This blend combines retatrutide and cagrilintide in one product. It is sold for maximum weight loss. Neither drug is approved, they belong to rival companies, and we found no trial that has combined them.

- **Legal lane:** no lawful route. Both ingredients are investigational drugs that cannot be prescribed or compounded.
- **Evidence grade:** D for the combination
- **What is in it:** retatrutide and cagrilintide
- **Established human dose:** none

## What it is

A premixed product sold by peptide suppliers and some clinics. The ingredients:

- **[retatrutide](https://aminodesk.com/library/retatrutide):** an investigational weight-loss drug from Eli Lilly; not approved.
- **[cagrilintide](https://aminodesk.com/library/cagrilintide):** an investigational amylin drug from Novo Nordisk; not approved, and the FDA has said it cannot be compounded.

The idea copies [CagriSema](https://aminodesk.com/library/cagrisema), which pairs cagrilintide with semaglutide and has been through large trials as a single product. Swapping in retatrutide makes a different combination that has not.

## What the evidence shows

We found no trial of this combination. The evidence that exists applies to each ingredient studied on its own, and each ingredient's page has its grade and what was shown.

Each drug has strong trial results on its own, in monitored studies with set doses and slow step-ups. Stacking two potent appetite drugs is not a small change. The side effects of each are mostly in the stomach and gut, and they would be expected to add up.

## Legal status

- **Retatrutide:** not approved. Available only in clinical trials.
- **Cagrilintide:** not approved, and the FDA has said it cannot be compounded.
- Anything sold as this blend comes from an unregulated supplier.

## Reported dosing

**No dose has been established for this blend.**

No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown.

## Safety

- If you improve, you cannot tell which ingredient did it. If you react, you cannot tell which one caused it.
- The ratio is fixed by the seller. You cannot adjust one ingredient without moving the other.
- No safety or absorption work exists on the mixture.
- Nausea, vomiting and dehydration are the predictable risks of combining two drugs of this kind.
- A vial from an unregulated supplier may not contain what the label says, in either identity or amount.

## Common questions

### What is in this blend?

Retatrutide and cagrilintide.

### Has this blend been tested in people?

We found no human trial of the combination.

### Is this blend legal?

No. Both ingredients are investigational drugs with no lawful route outside a clinical trial.

## Sources

- [Lilly: results for its amylin drug, for context on the amylin class](https://investor.lilly.com/node/53246)
- [Healthline: CagriSema, the tested cagrilintide combination](https://www.healthline.com/health/drugs/cagrisema-for-weight-loss)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
